Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

US expansion update

6 Jan 2023 07:00

RNS Number : 8680L
Omega Diagnostics Group PLC
06 January 2023
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega", the "Company" or the "Group")

 

US expansion update

 

Maiden US Laboratory FoodPrint® installation,

Appointment of US importer for FoodPrint® and

First PO from US CLIA certified Lab heralds start of US expansion

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the maiden purchase order ('PO') for its FoodPrint® system from a CLIA certified ('Clinical Laboratory Improvement Amendments') laboratory in the United States, and has appointed a new US importer for FoodPrint® kits.

 

Using a small finger prick of blood, the FoodPrint® test can quickly identify an individual's unique food sensitivity reactions, allowing the patient to adjust and plan to a new diet and address IgG-mediated food sensitivities. FoodPrint® analyses up to 222 foods for IgG antibodies and is trusted by more than 150 laboratories worldwide, to help fast track a guided elimination diet allowing a more focused and actionable result for practitioners and their patients.

 

The Board expects installation at the laboratory to commence later this month and after a period of validation and gaining necessary approvals, the processing of tests to begin later this quarter. As well as being CLIA certified, the laboratory receiving the system is also College of American Pathologists accredited and specialises in providing functional tests for both consumers and healthcare practitioners.

 

Omega has also secured an importer for FoodPrint® kits into the USA. The importer will import kits for the CLIA laboratory as well as for Omega's own direct channels in future.

 

Although the value of this initial PO is circa £50,000, the US market is a key area of focus for Omega's growth strategy and this installation will be the first in the US market in over seven years, representing the beginning of Omega's planned expansion into the USA.

 

Jag Grewal, CEO of Omega Diagnostics, said: "The US is the single largest market for food sensitivity testing globally, with an ever-increasing demand for personalised medicine, and is a focus area for our growth plans. This installation reflects a key milestone in our expansion plans, the receiving laboratory is ideally placed to commercialise FoodPrint® in the US market as they are already providing a range of other functional tests. The appointment of the US importer will act as a foundation for our expansion into the region.

 

"Once the system has been commissioned, we plan to collaborate closely with our laboratory partner to ensure FoodPrint® is promoted effectively through their existing healthcare practitioner and direct to consumer channels."

 

 

Contacts: 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

Alice Lane/Charlotte Sutcliffe (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBAMLTMTTMBAJ
Date   Source Headline
9th Oct 20097:00 amRNSTrading Update
2nd Oct 20093:20 pmRNSHolding(s) in Company
2nd Oct 20093:04 pmRNSHolding(s) in Company
2nd Oct 200912:16 pmRNSHolding(s) in Company
2nd Oct 20098:53 amRNSHolding(s) in Company
30th Sep 20097:00 amRNSHolding(s) in Company
30th Sep 20097:00 amRNSHolding(s) in Company
25th Sep 20097:00 amRNSIssue of equity and acquisition
27th Aug 200911:56 amRNSAGM Statement
17th Jul 20099:00 amRNSAnnual Financial Report
16th Jul 20097:00 amRNSUK Distribution agreement for Genesis products
7th Jul 20097:00 amRNSFinal Results
4th Jun 20097:00 amRNSHolding(s) in Company
26th May 20097:00 amRNSLaunch of quality performance product
6th Apr 20093:03 pmRNSDirector/PDMR Shareholding
2nd Apr 200911:41 amRNSTrading Statement
20th Mar 20092:00 pmRNSChange of Adviser
12th Dec 20083:48 pmRNSDirector/PDMR Shareholding
27th Nov 20087:00 amRNSInterim Results
11th Nov 20087:00 amRNSTrading Statement
8th Oct 20083:57 pmRNSChange of Adviser Name
28th Aug 20081:24 pmRNSAGM Statement
12th Aug 200810:51 amRNSIssue of Equity / Directors'
18th Jul 200811:30 amRNSAnnual Report and Accounts
7th Jul 20087:00 amRNSFinal Results
12th Jun 20087:00 amRNSNotice of Results
10th Apr 20087:18 amRNSTrading Statement
12th Mar 200811:59 amRNSDirector/PDMR Shareholding
11th Mar 20082:19 pmRNSDirector/PDMR Shareholding
4th Mar 20087:01 amRNSDirector/PDMR Shareholding
10th Jan 20082:28 pmRNSHolding(s) in Company
7th Dec 20077:01 amRNSInterim Results
28th Sep 20077:01 amRNSTotal Voting Rights
26th Sep 20077:01 amRNSNotifiable Interest
3rd Sep 20078:00 amRNSCompletion of Acquisition
3rd Sep 20078:00 amRNSTotal Voting Rights
31st Aug 20071:27 pmRNSDirectors' Dealings
31st Aug 20078:21 amRNSGenesis-CNS Interim Results
31st Aug 20078:00 amRNSCancellation - 31/08/07
30th Aug 200712:56 pmRNSResult of EGM
15th Aug 20078:23 amRNSCompliance with AIM Rule 26
13th Aug 200710:22 amRNSSchedule 1 -Omega Diagnostics
8th Aug 200712:26 pmRNSAGM Statement
6th Aug 20077:01 amRNSAcquisition and placing
6th Aug 20077:00 amRNSRestoration-Omega Diagnostics
6th Aug 20077:00 amRNSChange of Adviser
12th Jul 20071:30 pmRNSStatement re. Suspension
12th Jul 20071:30 pmRNSSuspension-Omega Diagnostics
26th Jun 20077:01 amRNSFinal Results
18th Apr 20074:50 pmRNSAccounting Reference Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.